https://www.live-feeds.com/feed/moderna-surges-as-merck-partnered-melanoma-vaccine-cuts-recurrence-in-large-trialContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/moderna-surges-as-merck-partnered-melanoma-vaccine-cuts-recurrence-in-large-trialhttps://www.live-feeds.com/feed/moderna-surges-as-merck-partnered-melanoma-vaccine-cuts-recurrence-in-large-trial#u47837Tue, 25 Aug 2026 03:50:21 +0000Moderna and Merck announced Wednesday that their experimental mRNA vaccine prevented melanoma from returning or spreading in high-risk patients. The personalized treatment successfully cleared phase 3 clinical trials, which is the final requirement before FDA approval. While the news initially drove a surge in Moderna stock, the company saw a 24% price drop on Thursday as the rally faded. The vaccine was used in combination with Merck's KEYTRUDA for patients with completely resected stage IIB-IV melanoma to improve recurrence-free and distant metastasis-free survival.Why it mattersPersona https://www.live-feeds.com/feed/moderna-surges-as-merck-partnered-melanoma-vaccine-cuts-recurrence-in-large-trialhttps://www.live-feeds.com/feed/moderna-surges-as-merck-partnered-melanoma-vaccine-cuts-recurrence-in-large-trial#u45499Thu, 20 Aug 2026 08:33:28 +0000Moderna and Merck's mRNA cancer vaccine, tested in a late-stage melanoma trial, met endpoints of recurrence-free survival and distant metastasis-free survival in patients with completely resected stage IIB-IV melanoma. The vaccine, known as Intismeran Autogene, was administered alongside Merck's KEYTRUDA. The trial results showed a significant reduction in cancer recurrence.Why it mattersThe success of this vaccine could mark a significant advancement in cancer treatment, offering new hope for patients with advanced melanoma. Melanoma is a serious form of skin cancer that can be fata